NEW YORK (GenomeWeb) – A study exploring the feasibility of treating melanoma patients with combination checkpoint inhibitors in the neoadjuvant setting also enabled researchers to explore immune characteristics and tumor markers that may predict response.
Researchers Explore Variety of Response Markers in Melanoma Study of Combo Checkpoint Inhibitors
Premium
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.